Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
COSMOS Pharmaceutical Corporation (3349.T)
JPY6,515.00
-103.00 (-1.56%)
JP JPX Healthcare Medical - Pharmaceuticals
Address
Fukuoka Daiichi Building 812-0013
Fukuoka City, JP
Fukuoka City, JP
CEO
Hideaki Yokoyama
Website
cosmospc.co.jp
IPO
2004-11-11
ISIN JP3298400007
Also trades on
Other OTC · CSMYF (USD)
Tokyo Stock Exchange · 3349.T (JPY)
Description
COSMOS Pharmaceutical Corporation manages an extensive network of drugstores throughout Japan. The company operates a significant 1,130 retail locations, strategically positioned across the Kanto, Chubu, Kansai, Chugoku, Shikoku, and Kyushu regions. Established in 1983, its primary office is situated in Fukuoka, Japan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY6,515.00
-103.00 (-1.56%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
429.3K
Beta
0.14
Float Shares
41.51M
Free Float %
52.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.55% | +0.02% | -0.51% | -13.35% | -19.51% | -22.26% | -31.93% | -10.00% | -21.05% | +24.02% | +1,816.18% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
6,515.00
Ratings Trend (MoM)
60% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | 0 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.75
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +9.5%+4.8% Q1'26: +10.9% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +18.1%+26.7% ★ Q1'26: +2.3% (vs Q1'25)
-
FCF margin Medical - Pharmaceuticals: +29.9%+2.7% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +4.8%+4.2% Q1'26: +4.2% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.0%+12.1% ★ Q1'26: +10.5% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: -0.1%+0.0% ★ Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Medical - Pharmaceuticals: -0.11×0.77× ★ Q1'26: 0.72× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
May 2015 actual |
May 2016 actual |
May 2017 actual |
May 2018 actual |
May 2019 actual |
May 2020 actual |
May 2021 actual |
May 2022 actual |
May 2023 actual |
May 2024 actual |
May 2025 actual |
May 2026 10 Rev. Ana. 10 EPS Ana. |
May 2027 10 Rev. Ana. 10 EPS Ana. |
May 2028 9 Rev. Ana. 9 EPS Ana. |
May 2029 4 Rev. Ana. 3 EPS Ana. |
May 2030 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
408.47B
est: 411.46B (-0.7%)
|
447.27B
est: 444.48B (+0.6%)
|
502.73B
est: 502.29B (+0.1%)
|
558.00B
est: 558.11B (0.0%)
|
611.14B
est: 611.77B (-0.1%)
|
684.40B
est: 677.00B (+1.1%)
|
726.42B
est: 727.81B (-0.2%)
|
755.41B
est: 755.84B (-0.1%)
|
827.70B
est: 826.15B (+0.2%)
|
964.99B
est: 966.16B (-0.1%)
|
1.01T
est: 1.01T (-0.1%)
|
1.09T
1.08T – 1.10T
+8.1% YoY
|
1.18T
1.14T – 1.20T
+7.6% YoY
|
1.26T
1.26T – 1.26T
+6.7% YoY
|
1.38T
1.35T – 1.39T
+9.5% YoY
|
1.47T
1.44T – 1.49T
+6.9% YoY
|
| EBITDA |
26.82B
est: 25.42B (+5.5%)
|
30.18B
est: 27.46B (+9.9%)
|
36.55B
est: 31.03B (+17.8%)
|
37.14B
est: 34.48B (+7.7%)
|
40.17B
est: 37.79B (+6.3%)
|
44.03B
est: 41.82B (+5.3%)
|
52.44B
est: 44.96B (+16.6%)
|
48.21B
est: 46.69B (+3.2%)
|
50.19B
est: 51.04B (-1.7%)
|
53.74B
est: 61.15B (-12.1%)
|
64.85B
est: 64.06B (+1.2%)
|
69.26B
68.42B – 69.65B
+8.1% YoY
|
74.49B
72.23B – 76.14B
+7.6% YoY
|
79.48B
79.48B – 79.48B
+6.7% YoY
|
87.03B
85.15B – 88.26B
+9.5% YoY
|
93.05B
91.05B – 94.38B
+6.9% YoY
|
| EBIT |
19.47B
est: 16.98B (+14.7%)
|
20.59B
est: 18.34B (+12.3%)
|
25.84B
est: 20.72B (+24.7%)
|
25.26B
est: 23.03B (+9.7%)
|
27.22B
est: 25.24B (+7.8%)
|
30.47B
est: 27.93B (+9.1%)
|
38.66B
est: 30.03B (+28.7%)
|
33.10B
est: 31.19B (+6.1%)
|
32.82B
est: 34.09B (-3.7%)
|
33.82B
est: 41.33B (-18.2%)
|
42.63B
est: 43.29B (-1.5%)
|
46.81B
46.24B – 47.07B
+8.1% YoY
|
50.34B
48.81B – 51.46B
+7.6% YoY
|
53.72B
53.72B – 53.72B
+6.7% YoY
|
58.82B
57.55B – 59.65B
+9.5% YoY
|
62.89B
61.53B – 63.78B
+6.9% YoY
|
| Net Income |
11.69B
est: 11.16B (+4.8%)
|
12.44B
est: 12.14B (+2.5%)
|
18.22B
est: 16.47B (+10.6%)
|
17.63B
est: 16.10B (+9.5%)
|
19.19B
est: 18.72B (+2.5%)
|
21.44B
est: 19.89B (+7.8%)
|
27.16B
est: 25.46B (+6.7%)
|
23.16B
est: 22.85B (+1.3%)
|
23.80B
est: 23.82B (-0.1%)
|
24.45B
est: 24.69B (-1.0%)
|
30.98B
est: 31.01B (-0.1%)
|
31.86B
31.21B – 32.70B
+2.7% YoY
|
33.08B
31.00B – 34.76B
+3.8% YoY
|
34.97B
32.80B – 38.17B
+5.7% YoY
|
40.66B
39.52B – 41.41B
+16.3% YoY
|
43.13B
41.92B – 43.93B
+6.1% YoY
|
| SGA |
54.10B
est: 59.40B (-8.9%)
|
59.44B
est: 64.17B (-7.4%)
|
68.10B
est: 72.51B (-6.1%)
|
76.68B
est: 80.57B (-4.8%)
|
85.05B
est: 88.32B (-3.7%)
|
93.35B
est: 97.73B (-4.5%)
|
99.16B
est: 105.07B (-5.6%)
|
107.76B
est: 109.11B (-1.2%)
|
122.81B
est: 119.26B (+3.0%)
|
138.54B
est: 139.48B (-0.7%)
|
152.43B
est: 146.11B (+4.3%)
|
157.96B
156.05B – 158.85B
+8.1% YoY
|
169.89B
164.74B – 173.67B
+7.6% YoY
|
181.29B
181.29B – 181.29B
+6.7% YoY
|
198.50B
194.22B – 201.32B
+9.5% YoY
|
212.24B
207.67B – 215.26B
+6.9% YoY
|
| EPS |
147.65
est: 140.81 (+4.9%)
|
157.01
est: 153.13 (+2.5%)
|
229.99
est: 207.82 (+10.7%)
|
222.64
est: 203.13 (+9.6%)
|
242.24
est: 236.19 (+2.6%)
|
270.65
est: 250.97 (+7.8%)
|
342.89
est: 321.21 (+6.8%)
|
292.37
est: 288.33 (+1.4%)
|
300.48
est: 294.34 (+2.1%)
|
308.61
est: 313.03 (-1.4%)
|
390.85
est: 392.60 (-0.4%)
|
402.00
393.73 – 412.61
+2.4% YoY
|
417.40
391.13 – 438.63
+3.8% YoY
|
441.25
413.84 – 481.54
+5.7% YoY
|
513.00
498.64 – 522.48
+16.3% YoY
|
544.20
528.96 – 554.26
+6.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-25 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-01 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-15 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-14 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-13 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-10 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
30.78B
OE per share TTM
388.46
Owner's Yield
6.46%
Maintenance CapEx ratio
44.23%
Maint CapEx / Avg PPE
29.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
7.73M
Shares Outstanding
79.26M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Futoshi Shibata | GM of Corporation Planning Department & Director | — | male |
| Hideaki Yokoyama | President & Representative Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3349.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
